ArriVent BioPharma (US.AVBP)
Capital Allocation Audit · Period: 2022 – 2026
Key Metrics
US.AVBP · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -13.4% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.00 | ↓ |
| Gross Margin | - | → |
US.AVBP (ArriVent BioPharma) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -13.4% ↑ Cash Conversion - → D/E Ratio 0.00 ↓ Gross Margin - →
Key Metrics
US.AVBP (ArriVent BioPharma) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -13.4% ↑Cash Conversion - →D/E Ratio 0.00 ↓Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies